Fairfield Financial Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Fairfield Financial Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$490K	Hold	1,098	–	–	0.17%	54
2025 Q4	$498K	Buy	1,098 +355	+48%	+$153K	0.16%	56
2025 Q3	$291K	Buy	+743	New	+$311K	0.1%	68
2025 Q1	–	Sell	-360	Closed	-$145K	–	200
2024 Q4	$145K	Sell	360 -5	-1%	-$2.32K	0.05%	77
2024 Q3	$170K	Sell	365 -11	-3%	-$5.28K	0.06%	79
2024 Q2	$176K	Buy	+376	New	+$163K	0.05%	70
2023 Q4	$144K	Hold	355	–	–	0.06%	87
2023 Q3	$123K	Hold	355	–	–	0.05%	86
2023 Q2	$125K	Hold	355	–	–	0.05%	85
2023 Q1	$111K	Hold	355	–	–	0.05%	93
2022 Q4	$103K	Hold	355	–	–	0.05%	91
2022 Q3	$103K	Hold	355	–	–	0.05%	85
2022 Q2	$100K	Sell	355 -40	-10%	-$10.7K	0.05%	82
2022 Q1	$103K	Buy	+395	New	+$93.7K	0.04%	84

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fairfield Financial Advisors's VRTX Position: Q1 2026 in Review

Fairfield Financial Advisors held its Vertex Pharmaceuticals (VRTX) position steady in Q1 2026 at 1,098 shares worth $490K. The position accounts for 0.17% of the portfolio, ranked #54.

Fairfield Financial Advisors first reported a position in VRTX in Q1 2022 and has held it in 14 quarters since. The position peaked at $498K in Q4 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Fairfield Financial Advisors held 1,098 shares of Vertex Pharmaceuticals worth $490K as of Q1 2026.
Fairfield Financial Advisors left its Vertex Pharmaceuticals share count unchanged in Q1 2026.
Vertex Pharmaceuticals made up 0.17% of Fairfield Financial Advisors's portfolio in Q1 2026, its #54 holding.
Fairfield Financial Advisors first reported a position in Vertex Pharmaceuticals in Q1 2022 and has held it in 14 quarters since.
Fairfield Financial Advisors's Vertex Pharmaceuticals position peaked at $498K in Q4 2025.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Fairfield Financial Advisors's 13F filing for Q1 2026, filed 27 Apr 2026.